Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Eisai to File Halaven for Soft Tissue Sarcomas; PIII Study Results Show Significant Prolongation of OS
February 26, 2015
- Takeda to Acquire Turkish Firm for Up to 14.5 Billion Yen, Earn 13 Branded Generics
February 25, 2015
- Daiichi Sankyo to Shake Up Japan Organization as Olmetec Patent Expiry Nears
February 25, 2015
- Japan’s 6th SGLT-2 Inhibitor Jardiance Hits Market
February 25, 2015
- US FDA Accepts NDA for Lonsurf: Taiho
February 24, 2015
- Takeda, Queen Mary University of London to Collaborate for Novel Drug Discovery in Gastroenterology Field
February 24, 2015
- MHLW OKs Additional Indications for E Keppra, Adempas
February 23, 2015
- Sun Pharma Wins Japan Approval for Cravit Generics, Competition with Daiichi Sankyo Might Arise
February 23, 2015
- J-Pharma Initiates PI Trial of LAT1 Inhibitor
February 23, 2015
- Pfizer Japan Receives Approval for Japan’s 1st Propecia Generic
February 23, 2015
- Bristol-Myers Files Eliquis for Venous Thromboembolism
February 20, 2015
- AnGes MG Changes Collategene Sales Partner in Japan from Daiichi Sankyo to Mitsubishi Tanabe
February 19, 2015
- Daiichi Sankyo Restores Lixiana Supply via Shipping Adjustment Following Demand Surge
February 19, 2015
- Daiwa Securities Unit Sets Up Venture Capital Fund to Support Drug Development
February 19, 2015
- Edoxaban Can Cover 80% of NOAC-Targeted Patients despite Restricted Use: US Commercial Chief
February 18, 2015
- Ono, Dako to Jointly Develop Companion Diagnostic Test for Opdivo
February 18, 2015
- MSD, Sanofi to Copromote RotaTeq, Heptavax in Japan
February 18, 2015
- Takeda to Terminate Asian PIII Study for Motesanib
February 18, 2015
- Nichi-Iko to Exclusively Market Plavix Authorized Generics
February 17, 2015
- Lenvatinib Obtains World’s 1st Approval in US: Eisai
February 17, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…